Synapse - Alexander Drilon

Search Within

Alexander Edward Drilon

Results (62)

A phase 2 study of cabozantinib for patients with advanced RET-rearranged lung cancers

Meeting Abstract

Drilon, A.; Somwar, R.; Smith, R.; Delasos, L.; Albano, M.; Van Voorthuyson, M.; Wang, L.; Rekhtman, N.; Ni, A.; Plodkowski, A.; more...
Journal of Thoracic Oncology (2017)

Fulltext@MSK | Save

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel

Journal Article

Smyth, L. M.; Monson, K. R.; Jhaveri, K.; Drilon, A.; Li, B. T.; Abida, W.; Iyer, G.; Gerecitano, J. F.; Gounder, M.; Harding, J. J.; more...
Investigational New Drugs (2017)

Fulltext@MSK | Save

Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies

Journal Article

Jordan, E. J.; Kim, H. R.; Arcila, M. E.; Barron, D.; Chakravarty, D.; Gao, J. J.; Chang, M. T.; Ni, A.; Kundra, R.; Jonsson, P.; more...
Cancer Discovery (2017)

Fulltext@MSK | Save

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

Journal Article

Drilon, A.; Rekhtman, N.; Arcila, M.; Wang, L.; Ni, A.; Albano, M.; Van Voorthuysen, M.; Somwar, R.; Smith, R. S.; Montecalvo, J.; more...
Lancet Oncology (2016)

Fulltext@MSK | Save

Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets

Journal Article

Rekhtman, N.; Pietanza, M. C.; Hellmann, M. D.; Naidoo, J.; Arora, A.; Won, H.; Halpenny, D. F.; Wang, H.; Tian, S. K.; Litvak, A. M.; more...
Clinical Cancer Research (2016)

Fulltext@MSK | Save

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program

Journal Article

Drilon, A.; Eaton, A. A.; Schindler, K.; Gounder, M. M.; Spriggs, D. R.; Harris, P.; Ivy, S. P.; Iasonos, A.; Lacouture, M. E.; Hyman, D. M.
Cancer (2016)

Fulltext@MSK | Save

What hides behind the MASC: Clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

Journal Article

Drilon, A.; Li, G.; Dogan, S.; Gounder, M.; Shen, R.; Arcila, M.; Wang, L.; Hyman, D. M.; Hechtman, J.; Wei, G.; more...
Annals of Oncology (2016)

Fulltext@MSK | Save

Toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of related and unrelated toxicities

Journal Article

Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E. G.; Drilon, A.; Vulih, D.; Smith, G. L.; Ivy, S. P.; Spriggs, D. R.; Hyman, D. M.
Clinical Cancer Research (2016)

Fulltext@MSK | Save

From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?

Journal Article

Plodkowski, A. J.; Drilon, A.; Halpenny, D. F.; O'Driscoll, D.; Blair, D.; Litvak, A. M.; Zheng, J.; Moskowitz, C. S.; Ginsberg, M. S.
Lung Cancer (2015)

Fulltext@MSK | Save

Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities

Meeting Abstract

Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E.; Drilon, A. E.; Vulih, D.; Smith, G. L.; Ivy, P.; Spriggs, D. R.; Hyman, D. M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save